Researchers at Stanford have developed methods to link antigenic or immunomodulatory molecules to bacterial surface proteins of commensal bacteria that result in a high immune response when applied to an epithelial surface of a mammal.
A team of Stanford researchers has developed humanized and chimeric mouse anti-human CD99 monoclonal antibodies with demonstrated activity against AML (acute myeloid leukemia) cells in vitro and in vivo.
Non-alcoholic steatohepatitis (NASH) is the most common liver disease, leading to cirrhosis and hepatocellular carcinoma (HCC). HCC is one of the most common cancers and has a dismal prognosis as currently available medical treatment only improves survival by a few months.
Introduction: Blood cell transfusion plays a vital role in modern medicineāsupporting surgery, obstetrics, trauma care, and cancer chemotherapy. In the US alone, more than 12 million red-cell units are consumed annually.
Stanford Medicine's Ji Research Group has developed a simple, quantitative method for detecting and characterizing gene fusions that uses DNA rather than RNA as analyte.
Stanford scientists have created a de novo protein design platform that designs binding proteins that specifically target antigens in the major histocompatibility complex (MHC).
Researchers at Stanford have identified a novel class of ribonucleic acid (RNA)-reactive groups that effectively modify the RNA by placing heteroaryl and aryl groups at the 2'-hydroxyl (OH) positions.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford scientists have developed a novel method to accelerate the development of T cell target probes known as Rapid Identification of Peptide-ligands from Protein Antigen (RIPPA).
Stanford researchers have developed a strategy for generating chimeric transcription factors that enables exhaustion-resistant CAR-T cells and can be generalized to a wide range of cell therapies.
Stanford and Northwestern scientists have discovered that Platelet Factor 4 (PF4) is a biomarker for lymphatic diseases, such as lipedema and lymphedema, and can reliably differentiate them from obesity, which is a common misdiagnosis.